Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ribociclib + Paclitaxel in Rb+ Advanced Breast Cancer
NCT02599363Phase 1Completed
- Sponsor
- Abramson Cancer Center
- Start
- Jan 2016
- Primary completion
- Mar 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ribociclib in breast cancer, sponsored by Abramson Cancer Center. Primary endpoint: Number of Adverse Events at 3 years. Started Jan 2016; status: completed.
02
Drugs
ribociclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT02599363.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02599363.